Bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) is recommended to be available as a routine commissioning treatment option in patients aged ≥14 years old for suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB and pre-extensively drug resistant (pre-XDR) TB within the criteria set out in this document.
The following documents may not be fully accessible for people using assistive technologies. If you would like to request a more accessible format, please email ENGLAND.CET@nhs.net